• Outstanding Seal
  • Antimicrobial properties
  • Promotes per-apical healing
  • Easy obturations and follow-up

BioRoot™ RCS. Succeed.

For more information on this exciting new product go to 


Article: Volume 43 Number 6 Page 567 - July/August 2016

Prev    Article P567    Next  Read article

  Dent Update 2016; 43: 567-574

Oral medicine:  Mouth Cancer for Clinicians Part 12: Cancer Treatment (Chemotherapy and Targeted Therapy)

CPD:  CPD  0:48   (closed)      Self assess

Feedback:  0 comments, 0 ratings


Abstract: A MEDLINE search early in 2015 revealed more than 250,000 papers on head and neck cancer; over 100,000 on oral cancer; and over 60,000 on mouth cancer. Not all publications contain robust evidence. We endeavour to encapsulate the most important of the latest information and advances now employed in practice, in a form comprehensible to healthcare workers, patients and their carers. This series offers the primary care dental team in particular, an overview of the aetiopathogenesis, prevention, diagnosis and multidisciplinary care of mouth cancer, the functional and psychosocial implications, and minimization of the impact on the quality of life of patient and family.

Clinical relevance: This article offers the dental team a brief overview of chemotherapy and targeted therapy.

Author notes: Nicholas Kalavrezos, FRCS, FFD RCSI, MD, Maxillofacial and Reconstructive Surgeon of The Head, Face and Neck, University College London Hospital and The Harley Street Clinic. Assistant Secretary, European Association of Cranio-Maxillofacial Surgery and Crispian Scully, CBE, FMedSci, DSc, FDS, MD, Co-Director, WHO Centre on Oral Health and General Health; Professor Emeritus, UCL, London, UK (crispian.scully@ucl.ac.uk).

Objective: To provide the dental team with an overview of chemotherapy and targeted therapy for the treatment of mouth cancer.